Drug Profile
CV 8102
Alternative Names: CV-8102Latest Information Update: 27 Nov 2023
Price :
$50
*
At a glance
- Originator CureVac
- Class Adjuvants; RNA; RNA vaccines; Viral vaccines
- Mechanism of Action DDX58 protein stimulants; Immunostimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Adenoid cystic carcinoma; Colorectal cancer; Head and neck cancer; Malignant melanoma; Squamous cell cancer
- No development reported Rabies
Most Recent Events
- 27 Nov 2023 Phase I development is ongoing for Adenoid cystic carcinoma (Late-stage disease, Monotherapy, Combination therapy, Second-line therapy or greater) in France, Germany, Spain (CureVac pipeline, November 2023)
- 27 Nov 2023 Phase I development is ongoing for Head and neck cancer (Late-stage disease, Monotherapy, Combination therapy, Second-line therapy or greater) in France, Germany, Spain (CureVac pipeline, November 2023)
- 27 Nov 2023 Phase I development is ongoing for Malignant melanoma (Late-stage disease, Monotherapy, Combination therapy, Second-line therapy or greater) in France, Germany, Spain (CureVac pipeline, November 2023)